Gland Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)
Gland Pharma Ltd · Outcome · 06 Nov 2026, 10:03 pm
Gland Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 18,336 (+23.3% YoY | +1.9% QoQ) ■ EBITDA: 4,840 (+54.2% YoY | -1.1% QoQ) ■ EBITDA Margin (%): 26.4 (+529 bps YoY | -78 bps QoQ) ■ PAT: 2,908 (+58.3% YoY | -8.3% QoQ) ■ EPS (INR): 17.6 (+58.0% YoY | -8.3% QoQ)
Original exchange filing (PDF)
More announcements from Gland Pharma Ltd
- Schedule of Investor Meet Intimation · 17 Nov 2026
- Allotment of 3739 Equity Shares on exercise of ESOPs · 16 Nov 2026
- Grant of Options to Purchase Securities · 16 Nov 2026
- Q2FY27 Earnings Call Transcript · 12 Nov 2026
- Gland Pharma Limited has issued Corporate Guarantee on behalf of Phixen SAS, wholly owned step down subsidiary of the Company · 12 Nov 2026
- Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026 · 09 Nov 2026
- Q2FY27 Earnings Call Recording · 07 Nov 2026
- Q2Fy27 Investors presentation · 06 Nov 2026
